Contributions
Abstract: EP1496
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neurodegeneration
Introduction: Multiple sclerosis (MS) is autoimmune demyelinating disorder of central nervous system. Brain atrophy is more prominent on the later stage of disease and correlates with MS progression. Increased intrathecal synthesis of free light chains (FLC) was shown to be highly sensitive marker of MS and also predicts early prognosis of disorder, but its probable association with brain atrophy remains to be elucidated.
Objectives: To find correlations of brain matter volumes with kappa and lambda FLC and their quotients. To identify difference in brain volume in patients with high FLC (more than 75 percentile) and low FLC (less than 25 percentile).
Aim: The aim of the study was to find association between FLC and brain volumes of MS patients.
Methods: 100 patients with MS were participated in the study. FLC-concentration in cerebrospinal fluid (CSF) and serum were measured by ELISA assay (Polignost Ltd., Russia). Quotients of kappa and lambda FLC were calculated. Normalized grey matter (GMV) , white matter (WMV) and brain volume (NBV) were measured using automatical brain morphometric technique called SIENAX.
Results: The concentration of kappa FLC and kappa quotient showed significant inverse correlation with NBV (kappa FLC: p=0.0045, r=-0.2845; kappa quotient: p=0.013, r=-0.3042). Intrathecal concentration of kappa FLC also had a trend to inverse correlation with GMV (p=0.0579, r=-0.1913). Additionally, lambda quotient inversely correlated with WMV (p=0.0032, r=-0.3571). We also showed that patients with higher level of kappa FLC and quotient kappa have decreased volume of NBV (kappa FLC: p=0.0047; quotient kappa: p=0.038) and GMV (kappa FLC: p=0.0297). Additionally, patients with higher level of lambda FLC had decreased WMV (p=0.0446) and NBV (p=0.0026).
Conclusions: In accordance with results of the study FLC can be a prognostic marker of brain atrophy and neurodegeneration.
Disclosure: Gleb Makshakov has received honoraria for lectures and speaking in the past 2 years from Genzyme and Roche. Natalia Totolyan has received honoraria for lectures and speaking from Genzyme, Janssen, Merck and Roche. Evgeniy Evdoshenko has received honoraria for lectures and speaking from Biogen, Novartis, Roche, Merc, Janssen, Sanofi, Generium, Genzyme. Alexander Skoromets - nothing to declare. Sergey Lapin - nothing to declare. Vladimir Nazarov - nothing to declare.
Abstract: EP1496
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neurodegeneration
Introduction: Multiple sclerosis (MS) is autoimmune demyelinating disorder of central nervous system. Brain atrophy is more prominent on the later stage of disease and correlates with MS progression. Increased intrathecal synthesis of free light chains (FLC) was shown to be highly sensitive marker of MS and also predicts early prognosis of disorder, but its probable association with brain atrophy remains to be elucidated.
Objectives: To find correlations of brain matter volumes with kappa and lambda FLC and their quotients. To identify difference in brain volume in patients with high FLC (more than 75 percentile) and low FLC (less than 25 percentile).
Aim: The aim of the study was to find association between FLC and brain volumes of MS patients.
Methods: 100 patients with MS were participated in the study. FLC-concentration in cerebrospinal fluid (CSF) and serum were measured by ELISA assay (Polignost Ltd., Russia). Quotients of kappa and lambda FLC were calculated. Normalized grey matter (GMV) , white matter (WMV) and brain volume (NBV) were measured using automatical brain morphometric technique called SIENAX.
Results: The concentration of kappa FLC and kappa quotient showed significant inverse correlation with NBV (kappa FLC: p=0.0045, r=-0.2845; kappa quotient: p=0.013, r=-0.3042). Intrathecal concentration of kappa FLC also had a trend to inverse correlation with GMV (p=0.0579, r=-0.1913). Additionally, lambda quotient inversely correlated with WMV (p=0.0032, r=-0.3571). We also showed that patients with higher level of kappa FLC and quotient kappa have decreased volume of NBV (kappa FLC: p=0.0047; quotient kappa: p=0.038) and GMV (kappa FLC: p=0.0297). Additionally, patients with higher level of lambda FLC had decreased WMV (p=0.0446) and NBV (p=0.0026).
Conclusions: In accordance with results of the study FLC can be a prognostic marker of brain atrophy and neurodegeneration.
Disclosure: Gleb Makshakov has received honoraria for lectures and speaking in the past 2 years from Genzyme and Roche. Natalia Totolyan has received honoraria for lectures and speaking from Genzyme, Janssen, Merck and Roche. Evgeniy Evdoshenko has received honoraria for lectures and speaking from Biogen, Novartis, Roche, Merc, Janssen, Sanofi, Generium, Genzyme. Alexander Skoromets - nothing to declare. Sergey Lapin - nothing to declare. Vladimir Nazarov - nothing to declare.